<DOC>
	<DOCNO>NCT00930059</DOCNO>
	<brief_summary>The purpose study evaluate effect PF-04447943 compare placebo cognitive , behavioral overall symptom Alzheimer 's disease ; evaluate safety tolerability PF-0444793 compare placebo ; determine level PF-04447943 plasma course study .</brief_summary>
	<brief_title>A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild moderate Alzheimer 's disease ( MMSE 1426 ) Good general health ( control condition Type 2 diabetes hypertension allow ) Use acetylcholinesterase inhibitor ( donepezil , rivastigmine , galantamine ) memantine within 12 week start study Significant cardiovascular disease past 6 month Illness Alzheimer 's disease could contribute cognitive impairment History stroke seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>PF-04447943</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>plasma concentration</keyword>
</DOC>